Car T-Cell Therapy
Blood test may predict response to CAR T-cell therapy
Patients with diffuse large B-cell lymphoma who achieved a durable response to axicabtagene ciloleucel showed evidence of lower circulating tumor DNA levels before and after treatment, according to results of a prospective study.
Understanding Patient Populations to Diversify Clinical Trials with Ankit Kansagra, MD
In this episode, Ankit Kansagra, MD, discusses his path into medicine, how medical institutions can address systemic diversity issues and his personal experience as a physician during the pandemic.
Innovative Technology and Personalized Cancer Care with Lance Baldo, MD
In this episode, Lance Baldo, MD, discusses the use of MRD testing, T-cell receptor profiling, and how lessons from the COVID-19 pandemic will help shape the future of cancer vaccines.
Researchers use ‘humanized’ CAR T cells to improve treatment durability for patients with ALL
The FDA approved the first chimeric antigen receptor therapy in 2017, authorizing tisagenlecleucel for treatment of children or young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.
FDA clears IND application for CAR-T to treat metastatic colorectal cancer
The FDA cleared an investigational new drug application for GCC19CART, a chimeric antigen receptor T-cell therapy designed to treat patients with relapsed or refractory metastatic colorectal cancer.
UCLA researchers receive $1 million to develop novel CAR T-cell therapies for melanoma
Cristina Puig-Saus, PhD, and Daniel S. Shin, MD, PhD, of UCLA Jonsson Comprehensive Cancer Center received a $1 million award from the U.S. Department of Defense for research into novel cell therapies for rare melanomas.
Roswell Park appoints CAR T-cell pioneer as new deputy director
Renier Brentjens, MD, PhD, has been appointed deputy director and chair of the department of medicine of Roswell Park Comprehensive Cancer Center.
FDA clears IND application for BCMA-directed allogeneic CAR-T to treat multiple myeloma
The FDA cleared an investigational new drug application for P-BCMA-ALLO1, a chimeric antigen receptor T-cell therapy designed to treat adults with relapsed or refractory multiple myeloma.
National Comprehensive Cancer Network issues guidance on third dose of COVID-19 vaccine
National Comprehensive Cancer Network updated its guidance on COVID-19 vaccination for patients with cancer following FDA authorization of a third mRNA vaccine dose for certain immunocompromised individuals.
COVID-19-driven shortage of tocilizumab may impact delivery of CAR T-cell therapy
The FDA has included tocilizumab among its list of drugs currently in shortage.